Testing the relationship between gut permeability, elevation of systemic lipopolysaccharides and chronic disease : A thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy at Massey University, Manawatu, New Zealand

Author: Gnauck, Anne

Date: 2016

Publisher: Massey University

Type: Thesis

Link to this item using this URL: http://hdl.handle.net/10179/9904

Massey University

Abstract

The aim of my thesis was to test whether an increase in the permeability of the gut is accompanied by an increase in the level of systemic lipopolysaccharides (LPS), also referred to as endotoxin. These two parameters were firstly concurrently determined in healthy women after the treatment with a single dose of aspirin which is thought to temporarily increase the paracellular permeability of the intestine. Gut permeability and the levels of systemic LPS in healthy women were then compared with those in women with Crohn’s disease (CD) as the latter are thought to have chronically elevated paracellular permeability of the gut. Both groups also ingested a high fat drink which is reported to results in the elevation of systemic LPS. In addition, faecal calprotectin, a biomarker of ongoing inflammation in the gut, and LPS-binding protein (LBP), a proposed indirect biomarker for the exposure to LPS in the systemic circulation, were determined both in healthy women and in those with CD. Data indicated that both temporary and chronic increase in the paracellular permeability of the small intestine can be reliably determined by the 3-h excretion of lactulose. Further the combination of levels of faecal calprotectin and 3-h excretion of lactulose and mannitol is the most sensitive tool to distinguish between healthy subjects and those with CD. Hence, it is evident that the combination of those three parameters can be used to assess gut health. In contrast, the current available methods for the direct assessment of the systemic level of LPS/endotoxin i.e. the Limulus Amebocyte Lysate (LAL) assay for the quantification of endotoxin or ELISAs for the quantification of LPS, are not reliable as the former is interfered by constituents of serum and the latter failed to detect LPS from sources other than those provided from the manufacturer of the kit. Hence, studies suggesting that the consumption of high fat meals lead to elevations of systemic endotoxin and those suggesting that levels of systemic endotoxin is associated with the onset of metabolic syndrome are questionable. It is therefore advisable to repeat those studies when accurate methods for the quantification of LPS/endotoxin in the systemic circulation are available.

Copyright: The Author